New AbbVie hepatitis C combination cures 93 to 97% with genotype 3
Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients
Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation
Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment
Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study
